Combination Therapy Shows Promise Against Aggressive Osteosarcoma

Scientists at St. Jude Children's Research Hospital have identified a potential therapeutic vulnerability in certain aggressive forms of osteosarcoma. A combination of therapies, involving EP300 degradation and AKT inhibition, significantly slowed tumor growth and prolonged survival in preclinical models of this pediatric bone cancer. This finding offers a much-needed new therapeutic avenue, as no new treatments have been approved for the disease in the last 40 years.